BACKGROUND: The purpose of this study was to determine whether treatment with granulocyte colony-stimulating factor (G-CSF), which mobilizes endothelial progenitor cells from bone marrow, can safely improve the clinical outcomes of patients with atherosclerotic peripheral artery disease (PAD). METHODS AND RESULTS:Thirty-nine patients with intractable PAD were randomly assigned to 3 groups: a negative control group (n=12) treated with conventional drug therapy; a positive control group (n=13) treated with conventional drug therapy plus bone marrow transplantation (BMT); and a G-CSF group (n=14) treated with conventional therapy plus subcutaneous injection of 2-5 microg/kg of recombinant human G-CSF once daily for 10 days. One month after treatment, subjective symptoms improved significantly in the G-CSF and BMT groups. Ankle-brachial pressure index and transcutaneous oxygen pressure increased significantly in the BMT and G-CSF groups, but no such improvements were seen in the group receiving conventional therapy alone. CONCLUSIONS:G-CSF improves the clinical signs and symptoms of patients with intractable PAD to the same degree as BMT does. This noninvasive treatment may thus represent a useful new approach to managing the disease.
RCT Entities:
BACKGROUND: The purpose of this study was to determine whether treatment with granulocyte colony-stimulating factor (G-CSF), which mobilizes endothelial progenitor cells from bone marrow, can safely improve the clinical outcomes of patients with atherosclerotic peripheral artery disease (PAD). METHODS AND RESULTS: Thirty-nine patients with intractable PAD were randomly assigned to 3 groups: a negative control group (n=12) treated with conventional drug therapy; a positive control group (n=13) treated with conventional drug therapy plus bone marrow transplantation (BMT); and a G-CSF group (n=14) treated with conventional therapy plus subcutaneous injection of 2-5 microg/kg of recombinant humanG-CSF once daily for 10 days. One month after treatment, subjective symptoms improved significantly in the G-CSF and BMT groups. Ankle-brachial pressure index and transcutaneous oxygen pressure increased significantly in the BMT and G-CSF groups, but no such improvements were seen in the group receiving conventional therapy alone. CONCLUSIONS:G-CSF improves the clinical signs and symptoms of patients with intractable PAD to the same degree as BMT does. This noninvasive treatment may thus represent a useful new approach to managing the disease.
Authors: Mary M McDermott; Luigi Ferrucci; Lu Tian; Jack M Guralnik; Donald Lloyd-Jones; Melina R Kibbe; Tamar S Polonsky; Kathryn Domanchuk; James H Stein; Lihui Zhao; Doris Taylor; Christopher Skelly; William Pearce; Harris Perlman; Walter McCarthy; Lingyu Li; Ying Gao; Robert Sufit; Christina L Bloomfield; Michael H Criqui Journal: JAMA Date: 2017-12-05 Impact factor: 56.272
Authors: Amish N Raval; Eric G Schmuck; Girma Tefera; Cathlyn Leitzke; Cassondra Vander Ark; Derek Hei; John M Centanni; Ranil de Silva; Jill Koch; Richard G Chappell; Peiman Hematti Journal: Cytotherapy Date: 2014-09-18 Impact factor: 5.414